We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03181308
Previous Study | Return to List | Next Study

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

This study is currently recruiting participants.
Verified October 2017 by Tracon Pharmaceuticals Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03181308
First Posted: June 8, 2017
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.
  Purpose
This is a multicenter, open-label, nonrandomized, Phase 1b, dose-escalation study of Carotuximab (TRC105) in combination with standard dose Nivolumab in patients with metastatic NSCLC.

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung Drug: Carotuximab (TRC105) Drug: OPDIVO Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Tracon Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Phase 2 dose of carotuximab (TRC105) plus nivolumab [ Time Frame: Approximately 2-8 months ]
    Safety and tolerability will be evaluated in order to determine a recommended Phase 2 dose for carotuximab when added to standard dose nivolumab in patients with metastatic NSCLC.


Secondary Outcome Measures:
  • Response rate [ Time Frame: Approximately 2-8 months ]
    Preliminary evidence of antitumor activity of carotuximab (TRC105) plus nivolumab will be evaluated, by assessing response rate.

  • Trough carotuximab (TRC105) concentrations [ Time Frame: Approximately 2-8 months ]
    Trough (pre-dose) serum carotuximab (TRC105) concentrations will be measured using validated ELISA methods.

  • Development of immunogenicity antibodies [ Time Frame: Approximately 2-8 months ]
    The formation of carotuximab (TRC105) anti-product antibodies (APA) will be evaluated.

  • Progression-free survival [ Time Frame: Approximately 2-8 months ]
    Preliminary evidence of antitumor activity of carotuximab (TRC105) plus nivolumab will be evaluated, by assessing progression-free survival.

  • Trough nivolumab concentrations [ Time Frame: Approximately 2-8 months ]
    Trough (pre-dose) serum nivolumab concentrations will be measured using validated ELISA methods.


Estimated Enrollment: 30
Anticipated Study Start Date: October 2017
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TRC105 plus Nivolumab Drug: Carotuximab (TRC105)
Anti Endoglin Antibody
Other Name: TRC105
Drug: OPDIVO
Programmed Death Receptor-1
Other Name: Nivolumab

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed metastatic non-small cell lung cancer (NSCLC) with disease recurrence or progression during or after prior platinum-containing doublet chemotherapy regimen

    1. Patients with an active oncogenic driver (e.g., epidermal growth factor [EGFR], activin-receptor-like kinase 1 [ALK1], or the proto-oncogene tyrosine-protein kinase ROS-1) must have progressed on or after a US Food and Drug Administration (FDA)- approved therapy for that aberration (Note: Previous treatment with a tyrosine kinase inhibitor and platinum-based doublets does not exclude the patient.).
    2. Patients who received adjuvant or neoadjuvant platinum-doublet chemotherapy (after surgery and/or radiation therapy) and developed recurrent or metastatic disease within 6 months of completing therapy are not excluded.
    3. Patients with recurrent disease > 6 months after adjuvant or neoadjuvant platinum- based chemotherapy, who also subsequently progressed during or after a platinum- doublet regimen given to treat the recurrence, are not excluded.
  2. Formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival) - Biopsy should be excisional, incisional, or core. Needle aspiration is insufficient.
  3. Programmed death ligand 1 (PD-L1) expression on ≥ 1% of tumor cells by validated immunohistochemistry assay
  4. Measurable disease by irRECIST
  5. Age ≥ 18 years
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  7. Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 or baseline (except alopecia or neuropathy)
  8. Adequate organ function as defined by the following criteria:

    1. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 times upper limit of normal (ULN) or ≤ 5 times ULN in cases of liver metastases
    2. Total serum bilirubin ≤ 1.5 times the ULN
    3. Absolute neutrophil count (ANC) ≥ 1500/μL
    4. Platelets ≥ 100,000/μL without transfusion support within 28 days prior to study treatment
    5. Hemoglobin ≥ 9.0 g/dL without transfusion support within 14 days prior to study treatment (erythropoietin or darbepoetin permitted)
    6. Serum creatinine ≤ 1.5 times the ULN or creatinine clearance > 30 mL/min by Cockcroft-Gault formula
    7. International normalized ratio (INR) from 0.8 to 1.2
  9. Willingness and ability to consent for self to participate in study
  10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  1. Autoimmune disease (Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions not expected to recur in the absence of an external trigger are permitted.)
  2. Condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.)
  3. History or active interstitial lung disease
  4. Immunosuppression, of any kind
  5. Prior therapy with T-cell therapy, including an immune checkpoint inhibitor
  6. Prior treatment with carotuximab (TRC105)
  7. Current treatment on another therapeutic clinical trial
  8. Receipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment (Note: If anticancer therapy was given within 28 days prior to starting study treatment, patients are not excluded if ≥ 5 times the elimination half-life of the drug has elapsed.)
  9. Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months (Note: The following are not considered to be major procedures and are permitted up to 7 days prior to study treatment: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures.)
  10. Prior chest radiotherapy ≤ 3 months, wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvic bones or equivalent), or limited field radiation for palliation ≤ 14 days prior to study treatment - Such patients must have recovered adequately from any side effects of such therapy.
  11. Hypertension defined as blood pressure (BP) systolic > 150 or diastolic > 90 mm Hg (Note: Initiation or adjustment of antihypertensive medication prior to study entry is allowed provided that the average of 3 BP readings prior to study treatment is ≤150/90 mm Hg.)
  12. Ascites or pericardial effusion that required intervention within 3 months prior to study treatment
  13. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease (Note: Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered over the 14 days prior to study treatment)
  14. Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment
  15. Deep venous thrombosis within 6 months prior to study treatment, unless the patient is anti-coagulated without the use of warfarin for ≥2 weeks prior to study treatment; in this situation, low molecular weight heparin is preferred
  16. Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia)
  17. Thrombolytic use (except to maintain IV catheters) within 10 days prior study treatment
  18. Known active viral or nonviral hepatitis or cirrhosis
  19. Any active infection requiring systemic treatment
  20. History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatment
  21. History of peptic ulcer within the past 3 months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days prior to study treatment
  22. History of gastrointestinal perforation or fistula in the 6 months prior to study treatment, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)
  23. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
  24. Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of carotuximab (TRC105). All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 3 months following last dose of carotuximab (TRC105). The definition of effective contraception is provided in Section 2.6.1 of this protocol.
  25. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181308


Contacts
Contact: Brian E Simpson 858 550 0780 ext 287 bsimpson@traconpharma.com
Contact: Bonne Adams badams@traconpharma.com

Locations
United States, Alabama
University of Alabama Recruiting
Birmingham, Alabama, United States, 35294
Contact: Sarah Hall         
Sponsors and Collaborators
Tracon Pharmaceuticals Inc.
Investigators
Principal Investigator: Francisco Robert, MD PI
  More Information

Additional Information:
Responsible Party: Tracon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03181308     History of Changes
Other Study ID Numbers: 105LC102
First Submitted: June 1, 2017
First Posted: June 8, 2017
Last Update Posted: October 12, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Nivolumab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs